Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
Clinical trial NCT02968849 · COMPLETED
Trial details
- NCT number
- NCT02968849
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-26
- Primary completion
- 2021-11-16
- Enrollment
- 5404
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.